Display options
Cite
Hajarizadeh B, Razavi-Shearer D, Merat S, et al. Liver Disease Burden of Hepatitis C Virus Infection in Iran and the Potential Impact of Various Treatment Strategies on the Disease Burden. Hepat Mon. 2016;16(7):e37234doi: 10.5812/hepatmon.37234.
Hajarizadeh, B., Razavi-Shearer, D., Merat, S., Alavian, S. M., Malekzadeh, R., & Razavi, H. (2016). Liver Disease Burden of Hepatitis C Virus Infection in Iran and the Potential Impact of Various Treatment Strategies on the Disease Burden. Hepatitis monthly, 16(7), e37234. https://doi.org/10.5812/hepatmon.37234
Hajarizadeh, Behzad, et al. "Liver Disease Burden of Hepatitis C Virus Infection in Iran and the Potential Impact of Various Treatment Strategies on the Disease Burden." Hepatitis monthly vol. 16,7 (2016): e37234. doi: https://doi.org/10.5812/hepatmon.37234
Hajarizadeh B, Razavi-Shearer D, Merat S, Alavian SM, Malekzadeh R, Razavi H. Liver Disease Burden of Hepatitis C Virus Infection in Iran and the Potential Impact of Various Treatment Strategies on the Disease Burden. Hepat Mon. 2016 Jun 14;16(7):e37234. doi: 10.5812/hepatmon.37234. eCollection 2016 Jul. PMID: 27642346; PMCID: PMC5018306.
Copy Download .nbib Format: NLM
Share it on

Hepat Mon. 2016 Jun 14;16(7):e37234. doi: 10.5812/hepatmon.37234. eCollection 2016 Jul.

Liver Disease Burden of Hepatitis C Virus Infection in Iran and the Potential Impact of Various Treatment Strategies on the Disease Burden.

Hepatitis monthly

Behzad Hajarizadeh, Devin Razavi-Shearer, Shahin Merat, Seyed Moayed Alavian, Reza Malekzadeh, Homie Razavi

Affiliations

  1. The Kirby Institute, UNSW Australia, Sydney, Australia.
  2. Center for Disease Analysis, Louisville, Colorado, USA.
  3. Liver and Pancreatobiliary Diseases Research Center, Digestive Diseases Research Institute, Tehran University of Medical Sciences, Tehran, IR Iran; Digestive Oncology Research Center, Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran, IR Iran.
  4. Baqiatallah Research Center for Gastroenterology and Liver Diseases, Baqiatallah University of Medical Sciences, Tehran, IR Iran; Middle East Liver Diseases Center, Tehran, IR Iran.

PMID: 27642346 PMCID: PMC5018306 DOI: 10.5812/hepatmon.37234

Abstract

BACKGROUND: Chronic hepatitis C virus (HCV) infection is emerging as the leading cause of viral hepatitis-related liver disease in Iran.

OBJECTIVES: This study estimated the current and future disease burden of HCV infection in Iran and assessed the impact of various strategies in access to HCV treatment on reducing the disease burden.

MATERIALS AND METHODS: A modelling approach was used to estimate the size of HCV infected population, and disease progression from 2014 to 2030. Literature review and expert consensus informed the model parameters. Base case scenario assumed the currently utilized Interferon (IFN)-based treatment. Five other scenarios assumed utilizing IFN-free direct acting anti-viral regimens with 1, the base case diagnosis and treatment uptake; 2, restricting treatment to severe liver fibrosis; 3, treatment uptake being doubled; 4, stepwise increase in treatment uptake (doubled by 2017, quadrupled thereafter); 5, targeting at least 90% reduction in HCV infections by 2030.

RESULTS: In 2014, an estimated 186,500 individuals are living with HCV infection in Iran (median age: 30 years). By 2030, this number will increase to 213,700, while three to four fold increase is expected in the case numbers of decompensated cirrhosis (DC, n = 620), hepatocellular carcinoma (HCC, n = 510), and liver disease death (n = 400), assuming the current diagnosis/treatment settings. As compared with the base case scenario, scenarios 1 and 2 will have a limited impact on HCV disease burden, while scenarios 3 and 4 will result in 45% - 49% decrease in the number of individuals living with HCV infection and 60% - 69% decrease in DC, HCC and liver disease deaths by 2030. For at least 90% reduction in HCV infections by 2030 (scenario 5), diagnosis and treatment rates should be increased to 12,000 and 9,000 individuals per year in 2016, respectively and to 24,000 and 18,000 individuals per year, respectively in 2018 onward.

CONCLUSIONS: An increasing burden of HCV-related liver disease is expected in Iran under the current diagnosis and treatment levels. Increased diagnosis and treatment uptake is required in combination with enhanced treatment efficacy to reduce the HCV burden. The relatively young age of the HCV infected population, provides an opportunity for timely interventions to avert the projected rising HCV disease burden in Iran.

Keywords: Decompensated Cirrhosis; Diagnosis; Epidemiology; Hepatitis C; Hepatocellular Carcinoma; Mortality; Public Health; Treatment

References

  1. Hepat Mon. 2012 Sep;12(9):e6618 - PubMed
  2. Eur J Gastroenterol Hepatol. 2010 Mar;22(3):270-7 - PubMed
  3. Clin Infect Dis. 2013 Aug;57 Suppl 2:S39-45 - PubMed
  4. Addiction. 2016 Feb;111(2):311-9 - PubMed
  5. J Public Health Policy. 2010 Dec;31(4):478-93 - PubMed
  6. Drug Alcohol Depend. 2008 Jan 11;93(1-2):141-7 - PubMed
  7. Hepat Mon. 2013 Dec 07;13(12):e13313 - PubMed
  8. Ann Intern Med. 2012 Dec 4;157(11):817-22 - PubMed
  9. Hepat Mon. 2013 Mar 12;13(3):e7723 - PubMed
  10. AIDS Patient Care STDS. 2010 Dec;24(12):753-62 - PubMed
  11. Int J Infect Dis. 2010 Sep;14 Suppl 3:e113-6 - PubMed
  12. Hemodial Int. 2010 Jul;14(3):253-62 - PubMed
  13. Int J Infect Dis. 2015 Nov;40:116-30 - PubMed
  14. Liver Int. 2011 Jul;31 Suppl 2:61-80 - PubMed
  15. Clin Infect Dis. 2013 Jul;57(2):230-6 - PubMed
  16. J Viral Hepat. 2015 Dec;22 Suppl 4:21-41 - PubMed
  17. Middle East J Dig Dis. 2011 Sep;3(2):110-4 - PubMed
  18. Clin Infect Dis. 2015 Jun 15;60(12):1829-36 - PubMed
  19. Hepatol Res. 2007 Feb;37(2):101-3 - PubMed
  20. Aliment Pharmacol Ther. 2015 Mar;41(6):497-520 - PubMed
  21. Lancet. 2015 Aug 22;386(9995):743-800 - PubMed
  22. Arch Iran Med. 2006 Oct;9(4):319-23 - PubMed
  23. Gastroenterology. 2002 May;122(5):1303-13 - PubMed
  24. Int J Drug Policy. 2007 Oct;18(5):359-63 - PubMed
  25. Nat Rev Gastroenterol Hepatol. 2013 Sep;10(9):553-62 - PubMed
  26. Nat Rev Gastroenterol Hepatol. 2015 May;12(5):284-92 - PubMed
  27. J Hepatol. 2014 Nov;61(1 Suppl):S45-57 - PubMed
  28. PLoS One. 2011;6(8):e23830 - PubMed
  29. Drug Alcohol Rev. 2012 Nov;31(7):918-24 - PubMed

Publication Types